NCT00928148View on ClinicalTrials.gov

The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

PHASE2CompletedINTERVENTIONAL

Enrollment

86

Participants

Timeline

Start Date

June 14, 2004

Primary Completion Date

November 20, 2004

Study Completion Date

November 20, 2004

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

DRUG

SPD465

50 or 75 mg once daily for 7 days

DRUG

Immediate Release Amphetamine Salt

25 mg once daily for 7 days

DRUG

Placebo

Once daily for 7 days

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Shire

INDUSTRY

NCT00928148 - The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter